| Date | TitleTitle | |||
|---|---|---|---|---|
| 04/02/22 | 12:06:51 | 4 Feb 2022 | Holding(s) in Company | |
| 02/02/22 | 07:00:09 | 2 Feb 2022 | £2.1 million contract | |
| 27/01/22 | 07:00:06 | 27 Jan 2022 | Trading Update | |
| 10/01/22 | 07:00:08 | 10 Jan 2022 | New Major Pharma Client for Schizophrenia Trials | |
| 16/12/21 | 07:00:05 | 16 Dec 2021 | Electronic Clinical Outcomes Assessment Contract | |
| 09/12/21 | 07:00:06 | 9 Dec 2021 | £1.0m Schizophrenia clinical trial contract | |
| 22/11/21 | 11:50:04 | 22 Nov 2021 | Holding(s) in Company | |
| 16/11/21 | 07:00:12 | 16 Nov 2021 | Grant of Options | |
| 02/11/21 | 07:00:05 | 2 Nov 2021 | Directorate Change | |
| 26/10/21 | 07:00:04 | 26 Oct 2021 | Contract for pivotal schizophrenia clinical trial | |
| 06/10/21 | 10:06:56 | 6 Oct 2021 | Holding(s) in Company | |
| 21/09/21 | 07:00:07 | 21 Sept 2021 | Interim Results |
| Date | TitleTitle | |||
|---|---|---|---|---|
| 04/02/22 | 12:06:51 | 4 Feb 2022 | Holding(s) in Company | |
| 02/02/22 | 07:00:09 | 2 Feb 2022 | £2.1 million contract | |
| 27/01/22 | 07:00:06 | 27 Jan 2022 | Trading Update | |
| 10/01/22 | 07:00:08 | 10 Jan 2022 | New Major Pharma Client for Schizophrenia Trials | |
| 16/12/21 | 07:00:05 | 16 Dec 2021 | Electronic Clinical Outcomes Assessment Contract | |
| 09/12/21 | 07:00:06 | 9 Dec 2021 | £1.0m Schizophrenia clinical trial contract | |
| 22/11/21 | 11:50:04 | 22 Nov 2021 | Holding(s) in Company | |
| 16/11/21 | 07:00:12 | 16 Nov 2021 | Grant of Options | |
| 02/11/21 | 07:00:05 | 2 Nov 2021 | Directorate Change | |
| 26/10/21 | 07:00:04 | 26 Oct 2021 | Contract for pivotal schizophrenia clinical trial | |
| 06/10/21 | 10:06:56 | 6 Oct 2021 | Holding(s) in Company | |
| 21/09/21 | 07:00:07 | 21 Sept 2021 | Interim Results |
